Nanotechnology Now - Press Release: NanoViricides, Inc. Participated In WHO Meeting On Dengue Therapeutics

Home > Press > NanoViricides, Inc. Participated In WHO Meeting On Dengue Therapeutics

Abstract:
Company to File Annual Report Shortly

NanoViricides, Inc. Participated In WHO Meeting On Dengue Therapeutics

WEST HAVEN, CT | Posted on October 20th, 2008

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that it participated in a meeting of international experts on Dengue Therapeutics held by the Special Programme for Research and Training in Tropical Diseases (TDR), of the World Health Organization (WHO), in Geneva, Switzerland on October 2, 2008.

"Viral load reduction was clearly recognized as an important goal in Dengue treatment at this meeting. Nanoviricides are well suited for Dengue treatment because they are specifically designed for viral load reduction. We believe that our novel nanomedicine-based direct antiviral approach will be of great value in combating the Dengue viruses," said Anil R. Diwan, PhD, President of the Company, who participated in the meeting.

In another note, the Company clarified that the deadline for filing its Annual Report on Form 10-K, within the thirty day grace period allowed, is October 29, 2008. The Company, its counsel, public auditors and internal accountants, are committed to finalizing and filing the report accordingly. The Company expects to file the Annual Report shortly. When the Company files its annual report, the "E" will be removed from the Company's symbol, changing it back to the normal NNVC. The presence of an "e" (i.e. NNVCE) does not constitute a trading halt or delisting of the company's stock. It resulted from the original filing date for the annual report being exceeded.

NIAID experts see dengue as an important potential threat to the US public health (http://www.nih.gov/news/pr/jan2008/niaid-08.htm). The mosquito vectors that carry dengue viruses have been found in 36 or more states. Human infections in southern states have also been reported. Worldwide, dengue is among the most important reemerging infectious diseases with an estimated 50 to 100 million annual cases and 22,000 deaths. Dengue has become endemic in many tropical countries. (www.iht.com/articles/2008/05/15/healthscience/13brod.php).

Dengue fever is caused by one of four dengue virus types. Most people when they get the first infection have mild disease. A second infection with a different type of dengue virus can lead to a severe and life-threatening form of dengue disease, called severe dengue or dengue hemorrhagic fever. Thus people who have had a primary infection are primed for a severe form of the disease. Dengue severity is expected to continue to increase worldwide.

There are currently no drug treatments or vaccines against dengue.

####

About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: